Park Medi World Limited (PARKHOSPS) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Cofacto Research Published November 05, 2026 6 min read

Park Medi World operates 16 multi-super-specialty hospitals across North India with 3,960 beds, and is the largest private hospital chain in Haryana and the Tricity. This quarter's print will speak to whether network occupancy recovers from 55.6% as new units ramp, and how much of the CGHS tariff hike's guided 7-7.5% ARPOB impact flows through in its first full quarter.

Quick Details

Results date	November 09, 2026
Quarter	Q2 FY 2026-2027
Previous quarter revenue	Rs. 4,757.09 Mn (Rs. 475.71 Cr)
Previous quarter PAT	Rs. 885.93 Mn (Rs. 88.59 Cr)
Previous quarter EBITDA margin	26.5% (EBITDA ex-other income)
Market cap	Rs. 10,559.15 Cr
CMP	Rs. 244.57

Park Medi World Limited Q2 Results Date and Time

The Board is scheduled to meet on Monday, November 09, 2026, to approve standalone and consolidated unaudited results for the quarter and half year ended September 30, 2026 (Regulation 29, SEBI LODR). The trading window for designated persons remains closed till end of business hours on November 11, 2026.

The Q2 FY27 earnings call is scheduled for November 11, 2026, at 10:00 a.m. IST. The results presentation will be filed and posted on November 09, 2026. Scheduled participants include Dr. Ankit Gupta (MD), Dr. Sanjay Sharma (Whole-Time Director & CEO), Mr. Rajesh Sharma (Group CFO) and Mr. Sudesh Sharma (Chief Strategy Officer & Group OSD Finance).

What to expect from Park Medi World Limited's Q2 FY27 results

The Q2 print will test whether occupancy recovers from Q1 FY27's 55.6% as Rudrapur's 330 beds (commissioned August 2, 2026) and any Narela beds ramp, against management's own framework that hospitals above 60% occupancy run 30-31% EBITDA while sub-60% units run 15-20%. The first full quarter of the October 2025 CGHS rate revision flows through, with management guiding a 7-7.5% ARPOB impact for FY27 (full effect Q2-Q4); Q1 ARPOB of Rs. 30,444 was already up ~12% YoY, within the 10-12% guided band.

Seasonal vector-borne admissions are a tailwind but milder than last year — Delhi recorded 597 dengue and 214 malaria cases by September 30, 2026, below comparable 2025 levels, though infections nearly tripled since August. Management's FY27 guidance path — revenue Rs. 2,080 Cr (+24%), EBITDA Rs. 530 Cr (+25%), blended EBITDA margin 26.7-27%, PAT Rs. 360 Cr and 4,740 beds by end-FY27 — remains the reference, with in-window announcements (Kanpur O&M, Prayagraj PPP) ratcheting capacity ambition toward ~6,660 beds by December 2028 versus the concall's 5,740-by-FY28 figure.

The call is also expected to address the reconciliation between the implied FY27 EBITDA margin of 25.48% from the guided Rs. 530 Cr on Rs. 2,080 Cr and the stated 26.7-27% band.

Key Things To Watch

Performance vs FY27 guidance tracking: Management's Q1 FY27 (August 4, 2026) guidance is the reference for this call.

FY27 revenue — Rs. 2,080 Cr (+24% growth) by FY27 — Q1 run-rate was Rs. 475.71 Cr; H1 pace vs the 24% guide is the check
FY27 EBITDA — Rs. 530 Cr (+25% growth) by FY27 — implied margin of 25.48% sits below the stated 26.7-27% blended band; reconciliation to be clarified
FY27 PAT — Rs. 360 Cr (+32% growth) by FY27 — implied margin 17.31%, consistent with the 17-18% PAT margin guide
Bed capacity — 4,740 beds by end FY27 and 5,740 by FY28 — reconcile with ratcheted announcement targets of ~6,300 and ~6,600 beds
Occupancy — FY27 to moderate from FY26's 64% — Q1 printed 55.6%; watch the Q2 print with Rudrapur and any Narela beds in the denominator

CGHS tariff flow-through and receivables: Q2 is the first full quarter of the October 2025 CGHS rate revision.

Guided 7-7.5% ARPOB impact for FY27 with full effect from Q2-Q4; quantify how much converts to EBITDA versus equipment/technology reinvestment
Debtor days vs 129 at FY26 and the ~Rs. 200 Cr receivables provision; peer evidence (Max Healthcare) shows the CGHS benefit arriving alongside a Rs. 2.5 bn QoQ receivables build on payment delays
92% of debtors are Central Government-related; management does not expect sub-100 debtor days within the next 6-9 months

Commissionings and capacity additions: 450 beds are slated to commission in November-December 2026.

Palam Vihar 100-bed extension (Park Platinum) operating from November 2026; Narela 200-bed commissioning targeted Q2 FY27 — no operational-status update was found in the window, so the Q2 filing/call must confirm it
Zirakpur (Mehar Hospital, 150+ beds, ~Rs. 107 crore all-cash) indicative completion December 03, 2026
Kanpur 300-bed asset-light O&M agreement (September 16, 2026) — commissioning expected by end of the current financial year

Rudrapur and Zirakpur ramp in new states: Rudrapur is the first entry into Uttarakhand, live since August 2, 2026.

Rudrapur (330 beds, 80% of V3 Healthcare acquired July 31, 2026 for Rs. 1,416 Mn) — guided Rs. 100 Cr revenue and Rs. 20-22 Cr EBITDA in year one; early occupancy trajectory is the check
Zirakpur — guided Rs. 70-75 Cr revenue and 25-26% EBITDA in first year (FY28)
Rudrapur/Zirakpur payer mix expected at 75-80% government insurance / 20-25% cash+TPA per management

Balance sheet and IPO proceeds confirmations: Debt elimination and IPO fund deployment are standing reconciliation items.

Confirm nil gross term debt at September 30, 2026 after the completed Rs. 3,800 Mn IPO debt repayment (gross term debt was Rs. 28 Cr as of March 31, 2026 vs Rs. 450 Cr in FY25)
Reconcile IPO utilization figures — Rs. 6,484.45 Mn vs Rs. 7,051.68 Mn stated as utilized; Rs. 648.32 Mn unutilized and reallocated to the Rudrapur acquisition
Promoter dilution to 75% mandated by December 2028 — timeline called 'too early' by management; any update on the ~8% divestment tied to acquisitions

Frequently Asked Questions

What EBITDA and PAT margins has Park Medi World guided for FY27?

Management guided a blended EBITDA margin of 26.7-27% for FY27, restated as 26-27% in the current year, with PAT margin of 17-18% (raised from the earlier 15-17% mid-to-long-term band). Q1 FY27 printed a 26.5% EBITDA margin and 18.6% PAT margin.

How much revenue will the Rudrapur hospital add for Park Medi World in its first year?

Management has guided Rudrapur to Rs. 100 Cr of revenue and Rs. 20-22 Cr of EBITDA in its first year of operations. The 330-bed, NABH-accredited hospital was commissioned on August 02, 2026 after Park acquired 80% of V3 Healthcare for Rs. 1,416 Mn.

How will the CGHS rate hike benefit Park Medi World?

Management guided a 7-7.5% ARPOB impact in FY27 from the October 2025 CGHS package-rate revision, with partial effect in Q1 and full impact from Q2-Q4. Management called it one of the most handsome hikes with Park the biggest beneficiary, but is conservatively booking 7.5% and earmarking gains for technology and equipment upgrades rather than margin expansion.

Will Park Medi World's newly added hospitals drag on profitability?

Management stated there will be no EBITDA loss in new units, with year-one EBITDA starting at 10-12%. The Mohali ramp-up is cited as the template — monthly revenue grew from Rs. 52 lakhs at acquisition to Rs. 23 crores, with EBITDA moving from 12-13% to ~26%.

Is Park Medi World debt-free after its IPO?

The company completed the full Rs. 3,800 Mn IPO debt repayment per its August 3, 2026 announcement, eliminating long-term debt; gross term debt had already fallen to Rs. 28 Cr as of March 31, 2026 from Rs. 450 Cr in FY25. Investors can watch for confirmation of nil gross term debt at September 30, 2026 in the Q2 filing.